{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-016967","form_type":"8-K","ticker":null,"cik":"0001835416","company_name":"Moringa Acquisition Corp","filed_at":"2024-02-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.860567+00:00","generated_at":"2026-06-05T15:41:55.074255+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Moringa Acquisition Corp signs definitive merger with Silexion at $62.5M valuation","bullets":["SPAC Moringa (MACA) enters Business Combination Agreement with Israeli oncology firm Silexion Therapeutics; pre-transaction equity value $62.5M.","SPAC sponsor to forfeit 1,567,000 founder shares; closing requires minimum unrestricted cash of $500K.","Silexion must deliver at least $3.5M in convertible loan financing proceeds by March 10, 2024, as a closing condition.","Transaction must close by August 19, 2024; no termination fees payable by either party.","Silexion is a clinical-stage biotech developing therapies for KRAS-mutant solid tumors."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-016967","json":"https://secwatch.observer/filing/0001213900-24-016967.json","markdown":"https://secwatch.observer/filing/0001213900-24-016967.md","text":"https://secwatch.observer/filing/0001213900-24-016967.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1835416/000121390024016967/0001213900-24-016967-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1835416/000121390024016967/ea0200686-8k_moringa.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T15:41:55.074255+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ffd73f5b8404c3c8761ba8d627280d62fb6697c0","claim":"Moringa Acquisition Corp entered into Business Combination Agreement with Silexion Therapeutics Ltd. valued at $62.5 million (effective 2024-02-21).","evidence_excerpt":"On February 21, 2024, Moringa Acquisition Corp, a Cayman Islands exempted company (“ Moringa ”, the “ Company ”, or the “ SPAC ”), together with its wholly-owned Israeli subsidiary (“ Merger Sub ”), entered into a business combination agreement (as the same may be amended, supplemented or otherwise modified from time to time, the “ BCA ”) with Silexion Therapeutics Ltd., an Israeli company (“ Silexion ”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1835416/000121390024016967/0001213900-24-016967-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"merger"},{"label":"Counterparty","value":"Silexion Therapeutics Ltd."},{"label":"Value","value":"$62.5 million"},{"label":"Effective","value":"2024-02-21"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}